An observational study in Contraception, Menorrhagia and Endometrial Hyperplasia, sponsored by Bayer. Completed at 1 site in Kazakhstan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-30.
Sponsored by Bayer · Observational
Mirena is used for long-term in Kazakhstan, and in our observational program we would like to study patients distribution per indications of Mirena, and also patient compliance within a year after Mirena insertion. For patients with all approved indications for Mirena use: contraception, treatment of menorrhagia and protection from endometrial hyperplasia during estrogen replacement therapy
182 studies on the registry are indexed under Menorrhagia; 33 are open to participants now.
This study's enrollment of 2,725 is above the median of 300 across 41 observational studies indexed under Menorrhagia.
Browse Menorrhagia studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
Exclusion Criteria:
Drug: Levonorgestrel (Mirena, BAY86-5028)
Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
Patient distribution per indication
Time frame: 12 months
Patient compliance
Time frame: 12 months
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer